Y Maurice Morillon 2nd
Overview
Explore the profile of Y Maurice Morillon 2nd including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
10
Citations
248
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Greiner J, Morillon 2nd Y, Schlom J
Immunotargets Ther
. 2021 Jun;
10:155-169.
PMID: 34079772
NHS-IL12 is a novel immunocytokine designed for delivery of IL-12 to the tumor microenvironment (TME). NHS-IL12 consists of two molecules of IL-12 fused to a human IgG1 (NHS76) recognizing DNA/histone...
2.
Pellom S, Smalley Rumfield C, Morillon 2nd Y, Roller N, Poppe L, Brough D, et al.
JCI Insight
. 2021 Mar;
6(7).
PMID: 33651712
There are approximately 44,000 cases of human papillomavirus-associated (HPV-associated) cancer each year in the United States, most commonly caused by HPV types 16 and 18. Prophylactic vaccines successfully prevent healthy...
3.
Morillon 2nd Y, Sabzevari A, Schlom J, Greiner J
Anticancer Res
. 2020 Sep;
40(10):5329-5341.
PMID: 32988851
Investigation of the efficacy and mechanisms of human immuno-oncology agents has been hampered due to species-specific differences when utilizing preclinical mouse models. Peripheral blood mononuclear cell (PBMC) humanized mice provide...
4.
Morillon 2nd Y, Su Z, Schlom J, Greiner J
J Immunother Cancer
. 2019 Jun;
7(1):150.
PMID: 31186063
Background: While significant strides in the treatment of metastatic bladder cancer have been made with immune checkpoint inhibitors, the treatment of carcinoma in situ and non-muscle invasive, non-metastatic (superficial) human...
5.
Morillon 2nd Y, Hammond S, Durham N, Schlom J, Greiner J
Oncotarget
. 2017 Nov;
8(43):73469-73482.
PMID: 29088720
Immunotherapy was significantly enhanced in a murine tumor model by combining a vaccine with a fusion protein designed to target the glucocorticoid-induced tumor necrosis factor (TNF) receptor related gene (GITR)...
6.
Jochems C, Hodge J, Fantini M, Fujii R, Morillon 2nd Y, Greiner J, et al.
Oncotarget
. 2016 Nov;
7(52):86359-86373.
PMID: 27861156
Natural killer (NK) cells are known to play a role in mediating innate immunity, in enhancing adaptive immune responses, and have been implicated in mediating anti-tumor responses via antibody-dependent cell-mediated...
7.
Morillon 2nd Y, Lessey-Morillon E, Clark M, Zhang R, Wang B, Burridge K, et al.
J Immunol
. 2016 Oct;
197(9):3504-3511.
PMID: 27694496
The use of nondepleting Abs specific for CD4 and CD8 is an effective strategy to tolerize CD4 and CD8 T cells in a tissue-specific manner. We reported that coreceptor therapy...
8.
Morillon 2nd Y, Manzoor F, Wang B, Tisch R
J Vis Exp
. 2015 May;
(99):e52709.
PMID: 25992870
The mechanisms that regulate the efficacy of thymic selection remain ill-defined. The method presented here allows in vivo analyses of the development and selection of T cells specific for self...
9.
Morillon 2nd Y, Martin A, Gojanovich G, Wang B, Tisch R
Arch Immunol Ther Exp (Warsz)
. 2015 Mar;
63(4):239-50.
PMID: 25790749
Type 1 diabetes (T1D) is an autoimmune disease in which the insulin-producing β cells are selectively destroyed. β cell-specific T cells are considered to be the major mediators of pathology....
10.
He Q, Morillon 2nd Y, Spidale N, Kroger C, Liu B, Sartor R, et al.
J Immunol
. 2013 Nov;
191(12):5858-66.
PMID: 24198282
Inefficient thymic negative selection of self-specific T cells is associated with several autoimmune diseases, including type 1 diabetes. The factors that influence the efficacy of thymic negative selection, as well...